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Background: The study aims were to assess the association of microﬂora between the paranasal sinus and the lower airways of children attending a
regional paediatric cystic ﬁbrosis centre and to determine the performance of an eradication treatment protocol for positive paranasal sinus samples.
Method: Paired nasal lavage and lower airway samples (cough swabs or sputum) were taken from 54 children with cystic ﬁbrosis (median age
11 years). Positive paranasal sinus samples received eradication treatment, using oral and sinonasal nebulised antibiotics.
Results: A correlation between paranasal sinus and lower airways was detected in 33/54 paired timed samples (p b 0.02). Of 4/54 children who
reported sinus symptoms, only 2 had paranasal sinus positive samples. 28 positive nasal lavage samples cultured 8 Pseudomonas aeruginosa (PA),
8 Staphylococcus aureus (SA) and 12 other bacterial pathogens. Eradication using sinonasal nebulised antibiotics and oral antibiotics showed a
success of 14/21 (67%) treated paranasal sinus positive samples at 1 month & 3 months after treatment. Success rate was 75% in the PA group and
71% in the SA group. Ongoing monitoring with nasal lavage will continue.
Conclusion: There was agreement between pathogens or lack of them found in the paranasal sinus and lower airways. Paranasal infection is often
asymptomatic in children with cystic ﬁbrosis. The eradication protocol for paranasal sinus pathogens had a good success rate.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The main cause of morbidity and mortality in cystic fibrosis
(CF) patients is a progressive lung disease [1–3] caused by
bronchiectasis secondary to chronic colonisation with opportunis-
tic bacteria including Pseudomonas aeruginosa (PA), Staphylo-
coccus aureus (SA) and Haemophilius influenzae (HI) [4–6]. The
paranasal sinuses and the nose have mucous membrane linings that
are identical to the lungs with the dysfunctional cystic fibrosis
transmembrane receptor (CFTR) causing altered mucus rheology,
therefore negatively affecting the function of mucociliary clearance
in managing bacterial infection.☆ Presented at the European Cystic Fibrosis Conference, Lisbon 2013.
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microorganisms has been documented in several studies [5–8],
revealing that the paranasal sinus provides an environment for
chronic colonisation and subsequently a reservoir for bacteria to
infect LA, which impacts on the pulmonary status of CF patients.
This has been shown to be of particular importance in the
post-transplant population [9–11]. Post-lung transplant patients
have been highlighted as high risk for re-infection of bacteria.
Walter et al. [11] demonstrated the re-infection rate post-lung
transplant with identical PA strains as found within the paranasal
sinuses of these patients, highlighting the reservoir effect of the
paranasal sinuses. Hansen et al. [8] highlighted the potential for
the paranasal sinuses to provide protection for opportunistic
bacteria, where evolution and resistance to antibiotics can occur
before being transmitted to the LA. Berkhout et al. [6] highlighted
the importance of paranasal sinus cultures in the care andll rights reserved.
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therapy provided for positive LA cultures, by allowing re-infection.
The 4 pairs of paranasal sinuses (i.e., maxillary, ethmoid,
sphenoid, and frontal) develop at various points during childhood.
The ethmoid and maxillary paranasal sinuses begin to develop
during the fourth month of gestation, and continue to grow,
reaching full size by early adolescence. The sphenoid paranasal
sinus begins to appear at the age of two years, and mature fully by
adolescence; and the frontal paranasal sinus tends to develop from
four years old [12].
To date, there is limited evidence in the treatment of paranasal
sinus infection in CF patients. Endoscopic sinus surgery (ESS)
has been shown to have limited impact on paranasal sinus
infections and pulmonary function in the CF patient [13,14].
Mainz and Koitschev [15] studied the improvement of primary
symptoms after ESS, including nasal discharge, nasal airway
obstruction and olfactory function; the improvement was short-
lived and did not prevent re-occurrence of paranasal sinus
symptoms. Leung et al. [10] compared participants undergoing
sinus surgery pre-transplantation and the re-infection rate of
bacteria post-transplant, showing no significant difference.
Derosiers and Salas-Prato [16] studied the effects of nebulised
therapy in patients post-paranasal sinus surgery based on
symptoms, including pain as well as a quality of life (QOL)
questionnaire. They found no differences in the outcomemeasures.
When compared with the study of placebo of isotonic saline,
against tobramycin treatment to the paranasal sinuses, there was no
reference to the eradication of bacteriology identified at the
initiation of treatment. There are studies that advocate early
treatment to eradicate microorganisms before chronic colonisa-
tion occurs and deterioration of lung function [17,18] which
would suggest that eradication is possible in the paranasal sinus in
children with CF.
Inhalation therapy has been successful for the eradication
of microorganisms of lower airway infections [18], therefore
providing data to support topical antibiotic treatment for sinus
eradication. Möller et al. concluded that topical antibiotic treat-
ment could be delivered to the sinuses using pulsating aerosol
devices, demonstrating an improvement in deposition in the
sinuses in comparison to non-pulsating administered aerosol drug
delivery methods [19].
The potential correlation between paranasal sinus and lower
airway bacteriology was determined in children with cystic
fibrosis in a single tertiary CF centre. A prospective audit was
then performed to assess the feasibility and performance of a
standardised local paranasal sinus pathogen eradication proto-
col that had been newly introduced into this centre.
2. Materials and methods
2.1. Participants
CF paediatric patients attending outpatient clinic appoint-
ments at the Royal London Children's Hospital (RLCH) were
invited to participate, inclusion criterion was any child over
5 years old, with the ability to understand and perform a nasal
lavage, following simple commands. In October 2012 the newnasal lavage sampling (Appendix 1) and treatment eradication
protocols were introduced (see below), LA sampling and treat-
ment protocols remained the same [20].
2.2. Primary symptoms
All participants were asked standardised questions regard-
ing sino-nasal symptoms that are commonly experienced. This
was prior to microbiological samples being taken and included
questions on sinus pain, nasal obstruction, excessive nasal
secretions or snoring [15].
2.3. Sampling
A sampling guideline was developed (Appendix 1), to collect
the paranasal sinus sample using nasal lavage [20,21]. Nasal
lavage was also used as part of a teaching session with the patient
for self-management of paranasal sinus symptoms, including
snoring, nasal dripping or nasal obstruction. The nasal lavage was
taken using NeilMed sinus rinse kits® with isotonic saline
solutions with a minimum of 50 ml used. The participant was
asked to lean forward and perform neck side flexion in order to
improve sinus drainage. The nasal lavage was performed for a
minimum of 5 s in each nostril whilst mouth breathing. The
contents of the nasal lavage were collected in a sterile plastic
container. Nasal lavage is recommended as the preferred method
of paranasal sinus sampling in several studies [5,20,21]. During
the same clinic appointment a LA sample was taken —
preferably a sputum sample, in the case of no sputum being
expectorated a cough swab sample was obtained. The samples
were all processed in the same laboratory using a CF approved
protocol [22]. LA samples were always obtained first to avoid
contamination from the nasal lavage.
2.4. Treatment eradication protocols
Treatment protocols for eradication of PA and SA from the
paranasal sinuses were adapted from the previously developed
ones for the eradication of LA bacterial growth. Three protocols
were written, the first was for the eradication of PA, the second
was for the eradication of SA, and the final was for the eradication
of all other pathogens grown in the paranasal sinus. If participants
grew the same pathogen in both their paranasal sinus and LA
samples, a combination of treatment was provided in order to
optimise the process of eradication. The treatment was guided by
the sensitivities of the organism found.
For the eradication of PA, the participant was providedwith oral
antibiotics (3 weeks of ciprofloxacin) and nebulised antibiotics
(28 days tobramycin solution for inhalation (150 mg nebulised by
Pari-sinus® [19] the remaining 150 mg inhaled via mouthpiece
into the lungs, twice a day) followed by 2 months of 1–
2 megaunits of Colistimethate sodium) twice a day by mouth-
piece. The sinonasal antibiotic solution would be administered
using the Pari-sinus® nebuliser to optimise delivery with a
pulsating aerosol, providing improved deposition in comparison
to conventional inhalation therapy [19]. The eradication protocol
for SA was the use of oral antibiotics for 2 weeks and Mupirocin
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treated using 2 weeks of antibiotics specific to sensitivities and
Mupirocin for 5 days.
2.5. Data analysis
The audit was registered and approved as a prospective data
collection study looking at the guidelines that have been introduced
to practice within the CF population at the RLCH (audit number
1118), registered with the clinical effectiveness unit at the Royal
London Hospital. Descriptive analysis was used for identifying
the participants, primary symptoms and eradication outcomes.
Differences between paranasal sinus and LA bacteriology were
analysed using the Wilcoxon signed-rank statistical test, with a
p value b 0.05 being statistically significant of a positive cor-
relation between nasal lavage and LA bacteria growth.
3. Results
3.1. Participants
Of the 117 patients that attend CF clinics at the Royal London
Children's Hospital (RLCH), 54 patients (46%) provided nasal
lavage samples as well as routine LA samples obtained at each
clinic appointment, 36 (31%) were deemed too young to perform
nasal lavage sampling, and the other 27 patients (23%) refused
to participate in nasal lavage sampling (Flowchart 1). Table 1
displays the characteristics of the 54 patients that supplied
paranasal samples. The median age was 11 years old (IQR 3).
3.2. Primary symptoms
Four patients complained of primary symptoms (they were
classed as nasal dripping, snoring and paranasal sinus blockage).
All other participants reported to have no paranasal sinus
symptoms during clinic consultations. Two symptomatic partic-
ipants, nasal dripping and snoring, had positive nasal lavage
samples, PA and SA respectively, which were treated as per the
eradication protocol. These participants with reported nasal
dripping and snoring did not eradicate on follow-up culture,
however both have reported a reduction in symptoms with
regular nasal lavage. The other two participants with a primaryTable 1
Descriptive statistics of 54 paediatric CF patients.
Parameter Total (n = 54)
Median age, years
Inter-quartile range
11
(9–12)
Male
(%)
29
(53)
Lung function
Median FEV1
Inter-quartile range
85.7%
(78.9–100.6)
Lower airway sampling
Cough swab (%)
Sputum (%)
49 (90%)
5 (10%)symptom, paranasal sinus blockage and nasal dripping, also
reported improvement of symptomswith regular nasal lavage with
continued negative nasal lavage samples at follow-up clinics.
3.3. Microbiology
Positive nasal lavage cultures were obtained in 27 (50%) of
54 patients with only 16 (30%) positive LA cultures from the
54 patients. Of those 27 positive nasal lavage samples, the most
prevalent microorganisms were PA and SA with 8 (30%)
cultures of both. The most frequent growth in the LA samples
was PA with 8 growths (50%). The paired LA samples were
taken at the same clinic as the nasal lavage samples, 9 patients
(17%) had a matching microorganism in both nasal lavage and
LA cultures, 24 patients had no growth in both their nasal
lavage and LA cultures and 13 (24%) patients had positive
nasal lavage cultures with negative LA cultures, the remaining
7 had mismatched positive cultures. Table 2 outlines the
matched paired paranasal sinus and LA samples provided. Of
the 9 matched paranasal sinus and LA samples, 4 were PA, 2
were SA, and the final 3 were Stenotrophomonas maltophilia.
A total of 3 patients (6%) had multiple microorganisms
cultured from nasal lavage samples provided, and all had negative
LA cultures, however 4 patients (7%) had multiple microorgan-
ism cultured from LA samples provided, with at least one ap-
pearing positive in the nasal lavage sample provided.
The Wilcoxon signed-rank statistical test showed a statisti-
cally significant (p = 0.02) correlation between the microflora
of the nasal lavage and LA samples taken throughout this centre
cohort.
3.4. Eradication
Treatment was provided to 21 (78%) of the 27 positive nasal
lavage samples, with eradication being successful in 14 (67%) of
the 21 treatments. Treatment was not provided to 6 patients— 1
was due to a reporting error, 3 due to chronic colonisation of PA
(based on PA antibodies with optical density N 2), 1 moving out
of catchment therefore transferring care to another centre, and the
final patient was admitted for intra-venous antibiotic treatment
due to a pulmonary exacerbation.
Of the 8 positive PA nasal lavage cultures treatment was
provided to 4 participants, with eradication of PA occurring in 3
(75%) patients. There were 6 patients (2 that received treatment)
having ongoing PA treatment using conventional inhalation
therapy. In the SA group treatment was provided to 7 of the 8
participants, with eradication of SA occurring in 5 (71%)
participants.
All patients had finished paranasal sinus treatment when
re-sampling was taken, however 2 patients that grew PA were
returned to conventional inhalation therapy, and none of the SA
participants had further therapy after completing eradication
treatment.
The one other participant that did not receive treatment
despite a positive nasal lavage culture (due to a reporting error)
on follow-up grew a positive LA sample with the same
microorganism (Achromobacter xylosoxidans) as previously
Table 2
Comparing bacteriology of paired paranasal sinus and LA culture results.
Paranasal sinus sample
Pseudomonas aeruginosa
(n = 8)
Staphylococcus aureus
(n = 8)
Other bacteria a
(n = 12)
Negative culture
(n = 26)
Lower airway samples Pseudomonas aeruginosa
(n = 8)
4 2 1 1
Staphylococcus aureus
(n = 3)
0 2 1 0
Other bacteria a (n = 6) 1 0 4 1
Negative culture
(n = 37)
3 4 6 24
a Other bacteria include (paranasal sinus sample number) [LA sample number] — Achromobacter xylosoxidans (1) [1], Enterobacter cloacae (1) [0],
methicillin-resistant Staphylococcus aureus (1) [1], Burkholderia multivorans (2) [0], Streptococcus pneumoniae (3) [0], and Stenotrophomonas maltophilia (4) [4].
452 P. Wilson et al. / Journal of Cystic Fibrosis 13 (2014) 449–454cultured on the nasal lavage sample. Treatment was provided,
and negative results were returned for both nasal lavage and
LA samples.
Following the eradication protocols, all nasal lavage and LA
cultures were repeated at 1 month and 3 months after receiving
eradication treatment, with no growth of the original bacteria
cultured. Despite eradicating the original microorganism in 14
participants, 4 had positive nasal lavage cultures for a different
microorganism on follow-up nasal lavage sampling.Paediatric Cohort 
at RLCH 
117
Too young to 
participate (<5) 
36
Refused to provide 
sinus sample 
27
Co
pa
Pa
samp
Positive nasal 
lavage and positive 
LA samples 
15
Positive nasal 
Lavage and 
negative 
LA samples 
13 
Flowchart 1. Patient flow4. Discussion
There was a statistically significant correlation between the
paranasal sinus and LA bacteriology within the cohort of paediatric
CF participants, providing similar results to the study performed by
Dosanjh et al. [23]. The comparison of positive nasal lavage and
LA negative participants (13/54) against negative nasal lavage and
LA positive participants (2/54) could highlight the possibility that
the paranasal sinus becomes infected before the LA. These resultsnsented to 
rticipation 
54
ired timed 
les obtained
54
Negative nasal 
lavage and 
negative LA 
samples 
24
Negative nasal 
Lavage and 
positive 
LA samples 
2 
through sampling.
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sinuses are potential areas for bacteria growth and evolution before
infecting the LA in CF patients [5–8,14]. There are more positive
nasal lavage samples provided than LA samples throughout
the period of testing with 27 versus 16 respectively, which is
contradictory to the findings of Bonestroo et al. [5] which have
more LA positive samples in children in comparison to upper
airway samples, taken using a nasal endoscopy. This may be due
to the increased risk of paranasal sinus infection early in children
before LA. It may also be attributed to LA sampling using cough
swabs rather than sputum samples in younger non-productive
children being less effective at capturing true LA bacteriology
[24,25]. The single patient that missed treatment for a positive
paranasal sinus culture due to a reporting error provides a very
useful single case study that without the treatment the micro-
organism migrated to the LA in the 2 month period between
clinic reviews. This information emphasises the need to have
regular monitoring of the paranasal sinus in CF patients, with
samples taken at every outpatient clinic appointment in order to
assess the paranasal sinus of every child with CF.
Primary symptoms were noted only in four participants
during clinic consultations, with only two having positive
paranasal sinus cultures. This could indicate that the positive
growth of pathogens within the paranasal sinus does not have
an association with symptoms. This information is important
for future practice as far more participants have positive
cultures but no symptoms, meaning that regular testing of the
paranasal sinus is needed and cannot be led only by complaints of
symptoms as done in other studies looking at chronic rhinosinusitis
in CF patients [26]. Further follow-up may highlight changes to
sinonasal sensations post-eradication. The use of the sino-nasal
outcome tool (SNOT-20) [27] may provide a more specific
measure of sino-nasal symptoms. The SNOT-20 questionnaire has
only been validated for the use of adults, and therefore would not
be a reliable measure for the paediatric population being assessed
in this paper.
Limited evidence exists to suggest optimum treatment methods
in the eradication of microorganisms in the paranasal sinus of CF
patients. The specifically designed treatment protocols that were
used have shown to be successful in eradicating paranasal sinus
microorganisms in the participants of this study, with over 70% of
participants eradicating the two main microorganisms (PA and
SA) cultured in CF. This may also add further evidence to support
the use of pulsating aerosol generating devices for the improved
delivery and deposition of antibiotics to the sinuses [19]. Derosiers
and Salas-Prato [16] discuss the use of sinonasal inhalation
therapy for quality of life; with both treatment group (inhaled
antibiotics) and normal saline group having statistically significant
improvements. Further adaptations will need to be made to
maximise the eradication protocols for all other microorganisms
that are cultured. The children that did not eradicate with the initial
programme have been progressed to more long term management
of their paranasal sinus, including regular treatment [21] with
sinus nebulised antibiotics (using the Pari-sinus® [19]) and a
routine airway clearance technique using nasal lavage as taught
during clinic appointments, allowing guidance to extend the
current protocols in place. There are other factors that could beimpacting on the eradication process, such as adherence to
treatment, or chronic colonisation of the paranasal sinus with
microorganisms. These results also provide important information
when considering the re-infection rate within the post-transplant
population, emphasising the importance of improved paranasal
sinus management of children with cystic fibrosis [10].
Limitations of this study include the use of cough swabs
for LA sampling, which may not provide accurate bacteriology
of the LA [24,25], and therefore may have led to data that does
not fully reflect the bacteriology comparisons of paranasal
sinus and LA samples within the paediatric population. Without
single nucleotide polymorphism (SNP) genotyping, it will be
difficult to identify the specificity of microflora grown in the
nasal lavage samples and the LA samples.
5. Conclusion
This study has demonstrated a statistically significant correla-
tion between the paranasal sinus and LA bacteriology in patients
with CF. Clinical implications suggest that close screening of
paranasal sinus pathogens in children with CF should be performed
routinely.
Routine monitoring of paranasal sinus pathogens allows for
early eradication treatment to delay LA infection. The results of
this paper suggest that when treatment is provided eradication
is possible. However, further research is required to formulate
eradication protocols and improve success ratios.
Paranasal sinus infection has been shown to be present in
asymptomatic children with cystic fibrosis, results that should
be taken into consideration in the management of children with
cystic fibrosis regardless of symptoms being present or not.
There were no conflicts in interest in developing the guidelines
or reviewing the data of this audit.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.03.003.
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